How Orphan Drugs Became a Highly Profitable Industry

May 8, 2018

(The Scientist) – As a result, hundreds of new rare-disease treatments have entered the market over the past few decades, and orphan drug development has become a highly profitable industry. While this has undoubtedly helped patients, there are downsides to this trend. Some economists and scientists suggest that companies have abused the financial incentives for rare-disease drug development, and they predict a coming backlash to the hefty price tags of these medications.

Posted by

Posted in News, Research Ethics

Recommended Reading